L3VLUP
ProSign in

MRNA · AMGN in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

MRNAAMGN
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • MRNA
  • AMGN
0102030202120222023202420252026
Holders and value by quarter
QuarterMRNAAMGN
Q3 20206 holders, $3.1bn16 holders, $16.3bn
Q4 202016 holders, $4.4bn19 holders, $14.0bn
Q1 202118 holders, $8.0bn16 holders, $14.5bn
Q2 202122 holders, $18.4bn23 holders, $13.8bn
Q3 202127 holders, $27.6bn24 holders, $11.6bn
Q4 202120 holders, $17.2bn21 holders, $10.4bn
Q1 202216 holders, $11.8bn23 holders, $9.9bn
Q2 202219 holders, $10.2bn28 holders, $9.7bn
Q3 202222 holders, $8.4bn21 holders, $7.9bn
Q4 202220 holders, $13.0bn24 holders, $9.3bn
Q1 202317 holders, $11.2bn22 holders, $8.4bn
Q2 202315 holders, $8.9bn26 holders, $7.4bn
Q3 202312 holders, $7.2bn26 holders, $8.7bn
Q4 20238 holders, $6.9bn24 holders, $8.4bn
Q1 20247 holders, $7.6bn25 holders, $6.7bn
Q2 202413 holders, $9.5bn20 holders, $8.0bn
Q3 202412 holders, $4.8bn21 holders, $8.8bn
Q4 202415 holders, $3.1bn20 holders, $8.2bn
Q1 202511 holders, $2.0bn25 holders, $12.0bn
Q2 202510 holders, $2.0bn20 holders, $10.2bn
Q3 20259 holders, $1.2bn17 holders, $10.4bn
Q4 202510 holders, $2.5bn19 holders, $18.0bn
Q1 20269 holders, $4.8bn15 holders, $21.4bn
Q2 20269 holders, $8.0bn23 holders, $24.9bn
MRNA

Moderna Inc

Holders
9
Reported value
$4.8bn
Buyers
17
Sellers
19

Breadth -2 among 91 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
AMGN

Amgen Inc

Holders
15
Reported value
$21.4bn
Buyers
17
Sellers
15

Breadth +2 among 91 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q1 2026

Among the 20 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only MRNA (5)

Baillie Gifford & Co, Brevan Howard Capital Management LP, Renaissance Technologies LLC, Two Sigma Investments LP, Voloridge Investment Management LLC

Only AMGN (11)

AllianceBernstein LP, Capital Research Global Investors, Dodge & Cox, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Neuberger Berman Group LLC, Quantbot Technologies LP, Squarepoint Ops LLC, T. Rowe Price Associates Inc

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →